207 related articles for article (PubMed ID: 24026861)
1. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
4. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
6. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
[TBL] [Abstract][Full Text] [Related]
8. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
10. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
Boukerroucha M; Josse C; ElGuendi S; Boujemla B; Frères P; Marée R; Wenric S; Segers K; Collignon J; Jerusalem G; Bours V
BMC Cancer; 2015 Oct; 15():755. PubMed ID: 26490435
[TBL] [Abstract][Full Text] [Related]
12. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
[TBL] [Abstract][Full Text] [Related]
13. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].
Yuan P; Xu Y; Ouyang T; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT; Li JF
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):282-6. PubMed ID: 19615284
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
Chen Y; Zhou J; Xu Y; Li Z; Wen X; Yao L; Xie Y; Deng D
Cancer Sci; 2009 Sep; 100(9):1663-7. PubMed ID: 19522853
[TBL] [Abstract][Full Text] [Related]
16. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
[TBL] [Abstract][Full Text] [Related]
17. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Xu Y; Diao L; Chen Y; Liu Y; Wang C; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Deng D; Narod SA; Xie Y
Ann Oncol; 2013 Jun; 24(6):1498-505. PubMed ID: 23406733
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
Cerne JZ; Zong L; Jelinek J; Hilsenbeck SG; Wang T; Oesterreich S; McGuire SE
Breast Cancer Res Treat; 2012 Aug; 135(1):135-43. PubMed ID: 22706629
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
